Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market
SCMP Tech / 4/22/2026
💬 OpinionSignals & Early TrendsIndustry & Market Moves
Key Points
- Eight mainland China-based companies, including five biotech firms, cleared Hong Kong listing hearings in April, positioning them to tap the city’s liquidity.
- The group includes Metis TechBio, an AI-powered drug developer, alongside firms working on autonomous driving and industrial robots.
- The wave of IPO preparation follows the China Securities Regulatory Commission’s push for private companies to list in Hong Kong.
- Hong Kong’s listing activity is being shaped by regulatory requirements tied to “so-called” structures mentioned in the report, indicating closer compliance expectations for applicants.
Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the city’s deep liquidity.
The influx, including an AI-driven drug discovery firm, a driverless technology developer and a maker of industrial robots, comes as the China Securities Regulatory Commission (CSRC) has been pushing private firms to list in Hong Kong. The market regulator has required companies that established so-called...
Continue reading this article on the original site.
Read original →Related Articles
Black Hat USA
AI Business
Build-in-Public: What I Learned Building an AI Image SaaS
Dev.to
LLMs Don't Fail — Execution Does: Why Agentic AI Needs a Control Layer
Dev.to
Unauthorized Access Raises Security Concerns Around Anthropic’s Mythos
Dev.to
AI built your codebase in 2 months. Who's going to maintain it?
Dev.to
